# Diagnostic reassessment in myeloproliferative neoplasms: the value of functional iron parameters and JAK2 allelic burden

**Authors:** Rita González-Resina, Sara España-Fernández de Valderrama, Ángeles Montañés, Valle Recasens, Gonzalo Caballero

PMC · DOI: 10.1007/s00277-026-06774-y · Annals of Hematology · 2026-01-24

## TL;DR

This study shows that combining iron-related blood tests with genetic data improves the accuracy of diagnosing two types of blood cancer, PV and ET.

## Contribution

The study demonstrates that TSI and JAK2 VAF are superior to ferritin in differentiating PV from ET.

## Key findings

- PV patients had significantly lower ferritin, TSI, and EPO compared to ET patients.
- TSI was a better discriminator of PV from ET than ferritin.
- JAK2 VAF was higher in PV and correlated inversely with iron parameters.

## Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (MPNs), often associated with mutations in JAK2, CALR, and MPL. Differentiating PV from ET can be challenging in borderline cases, particularly when hemoglobin (Hb), hematocrit (Hct) and erythropoietin (EPO) values are inconclusive. Functional iron parameters and JAK2 variant allele frequency (VAF) may provide additional discriminatory value. To assess the diagnostic utility of transferrin saturation index (TSI), serum ferritin, EPO, and JAK2 VAF in distinguishing PV from ET, and to evaluate their association with mutational profiles. We conducted a retrospective, single-center study including 260 adult patients diagnosed with PV or ET between 2009 and 2024. Demographic, clinical, molecular, and laboratory parameters—including ferritin, TSI, EPO, Hb, Hct, and JAK2 VAF—were analyzed. Comparative and correlation analyses were performed using appropriate statistical tests. Compared to ET, patients with PV had significantly lower ferritin (median: 35.65 vs. 95.05 ng/mL), TSI (12.9% vs. 21.64%), and EPO (2.23 vs. 6.11 mIU/mL), but higher Hb (17.7 vs. 14.3 g/dL) and Hct (54.6% vs. 43.0%) (all p < 0.001). TSI discriminated PV from ET better than ferritin (p < 0.001 vs. p = 0.128). Among JAK2-mutated cases, VAF was higher in PV than ET (median: 48% vs. 21%, p = 0.003). VAF correlated inversely with ferritin, TSI, and EPO, and positively with Hct. TSI and JAK2 VAF outperform ferritin as diagnostic markers to differentiate PV from ET. Integrating functional iron parameters with molecular data improves diagnostic accuracy, particularly in clinically ambiguous cases, and supports their inclusion in MPN diagnostic algorithms.

## Linked entities

- **Genes:** JAK2 (Janus kinase 2) [NCBI Gene 3717], CALR (calreticulin) [NCBI Gene 811], MPL (MPL proto-oncogene, thrombopoietin receptor) [NCBI Gene 4352]
- **Diseases:** Polycythemia vera (MONDO:0009891), essential thrombocythemia (MONDO:0005029), myeloproliferative neoplasms (MONDO:0020076)

## Full-text entities

- **Genes:** JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}, MFSD11 (major facilitator superfamily domain containing 11) [NCBI Gene 79157] {aka ET}, MPL (MPL proto-oncogene, thrombopoietin receptor) [NCBI Gene 4352] {aka C-MPL, CD110, MPLV, THCYT2, THPOR, TPOR}, HAMP (hepcidin antimicrobial peptide) [NCBI Gene 57817] {aka HEPC, HFE2B, LEAP1, PLTR}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}
- **Diseases:** TE (MESH:D005134), inflammation (MESH:D007249), polycythemia (MESH:D011086), VAF (MESH:D006316), MPN (MESH:D009369), primary (MESH:D010538), anemia (MESH:D000740), ET (MESH:D013920), thrombotic (MESH:D013927), hematological disorders (MESH:D006402), iron deficiency (MESH:D000090463), PV (MESH:D011087)
- **Chemicals:** ruxolitinib (MESH:C540383), iron (MESH:D007501), VAF (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** V617F, W515K, JAK2 (V617F, S505N, W515L

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12830395/full.md

---
Source: https://tomesphere.com/paper/PMC12830395